AngioDynamics (NASDAQ:ANGO) Cut to “Hold” at Wall Street Zen

AngioDynamics (NASDAQ:ANGO) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

ANGO has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, October 8th. Canaccord Genuity Group raised their price target on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

AngioDynamics Stock Performance

Shares of AngioDynamics stock opened at $13.37 on Friday. The business’s 50 day moving average price is $12.41 and its 200 day moving average price is $10.82. The company has a market cap of $550.84 million, a price-to-earnings ratio of -17.14 and a beta of 0.49. AngioDynamics has a one year low of $8.27 and a one year high of $13.99.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $75.71 million for the quarter, compared to the consensus estimate of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. AngioDynamics’s quarterly revenue was up 12.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.11) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. On average, analysts predict that AngioDynamics will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer purchased 10,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were purchased at an average cost of $11.15 per share, with a total value of $111,500.00. Following the purchase, the chief executive officer owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Lawrence T. Weiss bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 21st. The stock was bought at an average cost of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the transaction, the senior vice president directly owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 20,890 shares of company stock valued at $239,532 over the last quarter. 6.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently made changes to their positions in ANGO. Divisadero Street Capital Management LP boosted its stake in shares of AngioDynamics by 253.7% during the 2nd quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier’s stock valued at $33,683,000 after buying an additional 2,435,365 shares during the last quarter. Armistice Capital LLC increased its position in shares of AngioDynamics by 140.1% in the 1st quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier’s stock worth $19,663,000 after purchasing an additional 1,222,000 shares during the last quarter. UBS Group AG raised its stake in shares of AngioDynamics by 83.6% in the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after purchasing an additional 501,881 shares in the last quarter. Millennium Management LLC lifted its position in shares of AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after purchasing an additional 393,682 shares during the last quarter. Finally, Bastion Asset Management Inc. grew its stake in AngioDynamics by 31.8% in the third quarter. Bastion Asset Management Inc. now owns 1,264,003 shares of the medical instruments supplier’s stock worth $13,442,000 after purchasing an additional 304,960 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.